- Aerie Pharmaceuticals, Inc. stock price today and history
Aerie Pharmaceuticals, Inc. (AERI) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Aerie Pharmaceuticals, Inc. stock price
Aerie Pharmaceuticals, Inc. latest news:
BRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial
Aerie Pharmaceuticals Inc(AERI). * Aerie Pharmaceuticals(AERI) initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan. * Aerie Pharmaceuticals Inc (AERI) - for Rhopressa, U.S. FDA PDUFA goal date of February 28, 2018 Source text for Eikon: Further company coverage:
U.S. FDA panel backs Aerie's glaucoma drug Rhopressa
Aerie Pharmaceuticals Inc's(AERI) experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks. The panel voted 9-1 in favor of the drug, Rhopressa, the first in a new class of treatments for glaucoma, an eye condition that is the second-leading cause of blindness in the world.
UPDATE 1-U.S. FDA panel backs Aerie's glaucoma drug Rhopressa
Oct 13 (Reuters) - Aerie Pharmaceuticals Inc's
experimental glaucoma treatment should be approved, an advisory
committee to the U.S. Food and Drug Administration said on
Friday, after it found the benefits outweigh the risks.
Aerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment
Shares of Aerie Pharmaceuticals Inc. were halted for trading Friday, as the U.S. Food and Drugs Administration reviews a new drug application for a treatment for glaucoma and ocular hypertension. The FDA's dermatologic and opthalmic drugs advisory committee will meet at 8.30 a.m. Eastern to review Rhopressa, an eye drop which, if approved, would be the only once-daily product targeting the trabecular meshwork, which is the eye's main fluid drain and the tissue responsible for the pressure on the eyes felt in glaucoma. Glaucoma is a disease in which damage to the optic nerve leads to vision loss. It's the second leading cause of blindness, according to the Glaucoma Research Foundation. Aerie shares have gained 66% in 2017, while the S&P 500 has gained 14%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
AEterna Zentaris Inc.AEZS
Aethlon Medical, Inc.AEMD
Agile Therapeutics, Inc.AGRX
Agios Pharmaceuticals, Inc.AGIO
AgroFresh Solutions, Inc.AGFS